Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

What We're Reading

  • What We're Reading
    A Sampling of Highlights from the Literature
    Cancer Immunol Res March 1 2021 9 (3) 253-253;

In the Spotlight

  • In the Spotlight
    How to Reprogram Myeloma-Associated Macrophages: Target IKZF1
    Francesco De Sanctis and Vincenzo Bronte
    Cancer Immunol Res March 1 2021 9 (3) 254-254; DOI:10.1158/2326-6066.CIR-21-0026

Cancer Immunology at the Crossroads

  • Cancer Immunology at the Crossroads
    Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy
    Robert D. Leone and Jonathan D. Powell
    Cancer Immunol Res March 1 2021 9 (3) 255-260; DOI:10.1158/2326-6066.CIR-20-0791

Perspective

  • Perspective
    At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer
    Marina Chiara Garassino and Antoni Ribas
    Cancer Immunol Res March 1 2021 9 (3) 261-264; DOI:10.1158/2326-6066.CIR-21-0008

Research Articles

  • Research Articles
    The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages
    Dimitrios Mougiakakos, Christian Bach, Martin Böttcher, Fabian Beier, Linda Röhner, Andrej Stoll, Michael Rehli, Claudia Gebhard, Christopher Lischer, Martin Eberhardt, Julio Vera, Maike Büttner-Herold, Katrin Bitterer, Heidi Balzer, Magdalena Leffler, Simon Jitschin, Michael Hundemer, Mohamed H.S. Awwad, Martin Busch, Steffen Stenger, Simon Völkl, Christian Schütz, Jan Krönke, Andreas Mackensen and Heiko Bruns
    Cancer Immunol Res March 1 2021 9 (3) 265-278; DOI:10.1158/2326-6066.CIR-20-0555

    Lenalidomide treatment for multiple myeloma skews M2-like macrophages to an M1 phenotype because lenalidomide triggers IKZF1 degradation, increasing IRF5 expression and decreasing IRF4. Modulating IKZF1 levels might provide a way to control macrophage polarization for cancer treatment.

  • Research Articles
    Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin
    Jessica Wagner, Elizabeth Wickman, Timothy I. Shaw, Alejandro Allo Anido, Deanna Langfitt, Jinghui Zhang, Shaina N. Porter, Shondra M. Pruett-Miller, Heather Tillman, Giedre Krenciute and Stephen Gottschalk
    Cancer Immunol Res March 1 2021 9 (3) 279-290; DOI:10.1158/2326-6066.CIR-20-0280

    CAR T cells targeting the EDB splice variant of fibronectin, a pan-cancer solid tumor target, have potent antitumor activity in preclinical solid tumor models. They can target not only tumor cells but also the tumor vasculature.

  • Research Articles
    ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity
    Brian B. Haines, Agnieszka Denslow, Peter Grzesik, Jennifer S. Lee, Terry Farkaly, Jacqueline Hewett, Daniel Wambua, Lingxin Kong, Prajna Behera, Judith Jacques, Caitlin Goshert, Michael Ball, Allison Colthart, Mitchel H. Finer, Melissa W. Hayes, Sonia Feau, Edward M. Kennedy, Lorena Lerner and Christophe Quéva
    Cancer Immunol Res March 1 2021 9 (3) 291-308; DOI:10.1158/2326-6066.CIR-20-0609

    ONCR-177 is a next-generation oncolytic virus being tested in the clinic. Preclinical efficacy and safety are reported and highlight the treatment's use as a single-agent, as well as in combination with immune checkpoint blockade.

  • Research Articles
    IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D
    Máté Kiss, Lieselotte Vande Walle, Pedro H.V. Saavedra, Els Lebegge, Helena Van Damme, Aleksandar Murgaski, Junbin Qian, Manuel Ehling, Samantha Pretto, Evangelia Bolli, Jiri Keirsse, Pauline M.R. Bardet, Sana M. Arnouk, Yvon Elkrim, Maryse Schmoetten, Jan Brughmans, Ayla Debraekeleer, Amelie Fossoul, Louis Boon, Geert Raes, Geert van Loo, Diether Lambrechts, Massimiliano Mazzone, Alain Beschin, Andy Wullaert, Mohamed Lamkanfi, Jo A. Van Ginderachter and Damya Laoui
    Cancer Immunol Res March 1 2021 9 (3) 309-323; DOI:10.1158/2326-6066.CIR-20-0431

    IL1β is implicated in cancer progression. The authors show that IL1β promotes neutrophil accumulation in tumors and suppresses antitumor immunity independently of the inflammasome, suggesting that therapeutic inflammasome inhibition will not limit IL1β production in certain cancer types.

  • Research Articles
    The Tumor Microenvironment Impairs Th1 IFNγ Secretion through Alternative Splicing Modifications of Irf1 Pre-mRNA
    Antoine Bernard, Christophe Hibos, Corentin Richard, Etienne Viltard, Sandy Chevrier, Sophie Lemoine, Joséphine Melin, Etienne Humblin, Romain Mary, Théo Accogli, Fanny Chalmin, Mélanie Bruchard, Paul Peixoto, Eric Hervouet, Lionel Apetoh, François Ghiringhelli, Frédérique Végran and Romain Boidot
    Cancer Immunol Res March 1 2021 9 (3) 324-336; DOI:10.1158/2326-6066.CIR-19-0679

    TGFβ in the tumor microenvironment induces alternative splicing of the transcription factor IRF1, giving rise to a shortened isoform (IRF1Δ7) specifically in CD4+ Th1 cells. IRF1Δ7 inhibits Th1 IFNγ production, highlighting a potential target to boost antitumor responses.

  • Research Articles
    A Machine Learning Approach Yields a Multiparameter Prognostic Marker in Liver Cancer
    Xiaoli Liu, Jilin Lu, Guanxiong Zhang, Junyan Han, Wei Zhou, Huan Chen, Henghui Zhang and Zhiyun Yang
    Cancer Immunol Res March 1 2021 9 (3) 337-347; DOI:10.1158/2326-6066.CIR-20-0616

    Using a machine learning–based strategy, a multiparametric prognostic model was developed. The constructed 20-feature gradient-boosting survival classifier reproducibly identifies patients with hepatocellular carcinoma (HCC) that are at the greatest risk of HCC-related death.

  • Research Articles
    Notch-Regulated Dendritic Cells Restrain Inflammation-Associated Colorectal Carcinogenesis
    Lei Wang, Shuiliang Yu, Ernest R. Chan, Kai-Yuan Chen, Cui Liu, Danian Che, Amad Awadallah, Jay Myers, David Askew, Alex Y. Huang, Ivan Maillard, Dan Huang, Wei Xin and Lan Zhou
    Cancer Immunol Res March 1 2021 9 (3) 348-361; DOI:10.1158/2326-6066.CIR-20-0428

    Conventional dendritic cells (DC) play a key role in the anti-tumor immune response. The data show that Notch2 deletion in all cells or in only DCs promotes inflammation-associated colorectal carcinogenesis; targeting Notch2-controlled DCs could restrain colon cancer.

Back to top
PreviousNext
Cancer Immunology Research: 9 (3)
March 2021
Volume 9, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • What We're Reading
  • In the Spotlight
  • Cancer Immunology at the Crossroads
  • Perspective
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Characterization of Murine Syngeneic Tumor Models
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement